The latest analysis draws from the randomized, placebo-controlled STOPMD-3 trial, a cornerstone in Sound Pharmaceuticals’ ongoing clinical development of SPI-1005 for Ménière’s disease. While the primary endpoints of the STOPMD-3 trial focused on vertigo control, this subsequent, comprehensive post-hoc analysis meticulously examined the auditory outcomes, providing a deeper understanding of the drug’s effect on hearing function. This detailed investigation into hearing improvements holds particular significance as Ménière’s disease is characterized by a fluctuating, often progressive, sensorineural hearing loss, alongside debilitating vertigo, tinnitus, and aural fullness. The company’s proactive approach to exploring all facets of its trial data exemplifies a commitment to uncovering the full therapeutic potential of SPI-1005.

In-Depth Look at Phase 3 Hearing Outcomes

The STOPMD-3 trial was a multicenter, randomized Phase 3 study involving 221 adults diagnosed with definite Ménière’s disease. Participants were randomly assigned to receive either SPI-1005 at a dose of 400 mg twice daily or an identical-looking placebo for a 28-day treatment period. Comprehensive hearing assessments were meticulously conducted at baseline, followed by evaluations at 28, 56, and 84 days post-treatment initiation. The primary auditory measures included pure-tone audiometry to assess hearing thresholds across three to four low-to-mid frequencies, and the Words-in-Noise (WIN) test, a sophisticated measure of speech understanding in challenging listening environments.

According to the scientific abstract presented at the AAO-HNS meeting, the per-protocol analysis, which included 191 participants (95 in the active-treatment group and 96 receiving placebo), revealed compelling results. At the 84-day mark, the researchers reported significant differences favoring the SPI-1005 treatment group across several key auditory metrics. Patients treated with SPI-1005 demonstrated a marked improvement in their pure-tone average hearing thresholds compared to the placebo group, indicating a restoration or preservation of hearing sensitivity. Furthermore, the analysis showed enhanced speech understanding capabilities among those receiving SPI-1005, as measured by the Words-in-Noise test, suggesting a crucial functional benefit for patients in real-world communication scenarios. While the exact numerical values for these improvements were not explicitly detailed in the original bullet points, the consistent reporting of "statistically significant differences" strongly implies a clinically meaningful effect.

A particularly insightful aspect of the analysis involved a subgroup of participants who presented with an average sensorineural hearing loss of at least 30 dB at baseline. In this more severely affected cohort, researchers observed even more pronounced and statistically significant differences favoring SPI-1005 for several hearing measures. While not every speech-understanding comparison in this subgroup reached conventional statistical significance, the overall trend indicated a beneficial effect, especially in those with greater baseline hearing impairment. This finding could be instrumental in identifying patient populations most likely to benefit from SPI-1005 therapy.

Following the initial 84-day controlled phase, many participants transitioned into an open-label extension study. During this extension, researchers continued to track hearing outcomes, reporting that improvements in hearing thresholds and Words-in-Noise performance persisted and, in some cases, continued to evolve among certain participants through 12 months of sustained treatment. However, the absence of a concurrent placebo comparison during this open-label phase necessitates a cautious interpretation, as it limits definitive conclusions regarding the sustained efficacy of SPI-1005 compared to natural disease progression or other factors. Nevertheless, the long-term observation of continued benefits offers encouraging preliminary data on the drug’s durability.

Ménière’s Disease: A Chronic Challenge

Ménière’s disease is a chronic and progressive disorder of the inner ear that affects balance and hearing. Characterized by a tetrad of symptoms—recurrent episodes of debilitating vertigo, fluctuating low-frequency sensorineural hearing loss, tinnitus (ringing in the ears), and aural fullness—it significantly impacts patients’ quality of life. The exact pathophysiology remains elusive, but it is widely believed to involve an imbalance of fluid within the inner ear, known as endolymphatic hydrops, which leads to dysfunction of the vestibular and cochlear systems.

Current management strategies for Ménière’s disease are largely symptomatic and aimed at reducing the frequency and severity of vertigo attacks, often without addressing the underlying hearing loss directly. These include lifestyle modifications, dietary changes (e.g., low-sodium diet), diuretics, anti-vertigo medications, and in more severe or refractory cases, intratympanic injections of corticosteroids or gentamicin, or even surgical interventions like endolymphatic sac decompression or labyrinthectomy. Despite these options, there remains a substantial unmet medical need for an effective, disease-modifying oral treatment that can improve or stabilize hearing, mitigate tinnitus, and control vertigo. SPI-1005, with its demonstrated ability to improve hearing metrics, represents a significant step towards addressing this critical gap.

SPI-1005: A Novel Therapeutic Approach

SPI-1005 is an investigational oral anti-inflammatory drug containing ebselen, a synthetic organoselenium compound. Its therapeutic mechanism of action is rooted in its ability to mimic and enhance the activity of glutathione peroxidase (GPx), a crucial endogenous enzyme system. GPx plays a vital role in the body’s antioxidant defense network, protecting cells from oxidative stress by catalyzing the reduction of harmful reactive oxygen species (ROS), such as hydrogen peroxide and lipid hydroperoxides, into less damaging molecules.

Oxidative stress, an imbalance between the production of free radicals and the body’s ability to counteract their harmful effects, is increasingly implicated in the pathophysiology of various inner ear conditions, including Ménière’s disease, noise-induced hearing loss, and ototoxicity from certain drugs. By augmenting GPx activity, SPI-1005 is hypothesized to reduce oxidative damage to the delicate hair cells and neuronal structures within the cochlea and vestibular system. This protective action could help preserve cellular integrity, reduce inflammation, and ultimately lead to improved auditory and vestibular function. The oral administration route of SPI-1005 is also a significant advantage, offering a non-invasive and convenient treatment option compared to direct intratympanic injections or surgical procedures.

Broader Implications: Sudden Sensorineural Hearing Loss (SSNHL)

Beyond Ménière’s disease, the robust hearing improvements observed in the STOPMD-3 trial have sparked considerable interest in SPI-1005’s potential for treating sudden sensorineural hearing loss (SSNHL). SSNHL is defined as a rapid-onset hearing loss, typically occurring within 72 hours or less, affecting at least three contiguous audiometric frequencies by 30 dB or more. It is considered an otologic emergency, requiring prompt diagnosis and intervention to maximize the chances of hearing recovery.

The current standard of care for SSNHL predominantly involves corticosteroids, administered either systemically (orally) or locally (intratympanically). While corticosteroids are effective for many patients, a significant proportion still experience incomplete recovery, highlighting the need for alternative or adjunctive therapies.

Sound Pharmaceuticals believes the compelling hearing improvements documented in Ménière’s patients could provide a compelling rationale for investigating SPI-1005 in SSNHL. Both conditions can manifest with unilateral sensorineural hearing loss, often affecting the lower frequencies, and are believed to involve elements of inflammation and oxidative stress within the inner ear. The potential overlap in underlying pathological mechanisms, despite differing clinical courses and etiologies, suggests that a drug targeting oxidative stress and inflammation could offer therapeutic benefits across both indications.

However, it is crucial to emphasize that the current analysis does not establish SPI-1005 as an effective treatment for sudden sensorineural hearing loss. The STOPMD-3 trial specifically enrolled patients with Ménière’s disease, and its findings cannot be directly extrapolated to SSNHL. To determine whether SPI-1005 offers benefits for SSNHL, dedicated, well-designed clinical studies involving patients specifically diagnosed with this condition will be absolutely necessary. This responsible approach underscores the company’s commitment to scientific rigor and evidence-based medicine.

A Timeline of Progress and Regulatory Milestones

Sound Pharmaceuticals has been steadily advancing SPI-1005 through its clinical development pipeline, marked by several significant milestones:

  • Late 2025: The U.S. Food and Drug Administration (FDA) granted SPI-1005 Breakthrough Therapy Designation for hearing loss associated with Ménière’s disease. This designation is reserved for therapies that demonstrate preliminary clinical evidence of substantial improvement over available therapies on a clinically significant endpoint, and it is intended to expedite the development and review process for promising new drugs.
  • Prior to Breakthrough Designation: SPI-1005 had already received Fast Track Designation for Ménière’s disease from the FDA. This designation aims to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.
  • July 2026: The company announced the successful completion of enrollment in a separate Phase 3 open-label study. This study is specifically designed to gather additional long-term safety data, which is crucial for supporting potential regulatory submissions for longer-term treatment durations.
  • October 19, 2026: Sound Pharmaceuticals publicly highlighted the statistically significant differences observed between the treatment and placebo groups across several hearing measures and follow-up periods in its announcement regarding the AAO-HNS presentation.

These regulatory designations, while not constituting FDA approval, signify the agency’s recognition of the potential importance of SPI-1005 in addressing a serious condition with an unmet need. They provide a clear pathway for accelerated development and review, bringing the possibility of a new treatment closer to patients. Cumulatively, Sound Pharmaceuticals reports that 15 ongoing and completed clinical trials for SPI-1005 have enrolled more than 980 patients across multiple indications, illustrating the breadth of investigation into this promising compound.

Leadership’s Perspective and Industry Recognition

The recognition received at the AAO-HNS Annual Meeting underscores the scientific community’s positive reception of Sound Pharmaceuticals’ research. Dr. Jonathan Kil, Co-Founder and CEO of Sound Pharmaceuticals, expressed his gratitude, stating, "We are honored to receive this recognition from the AAO-HNS and thank the reviewing committee." This award, "Best in Scientific Orals," is a testament to the quality of the scientific presentation, the robustness of the data, and the potential impact of the research on clinical practice. It signifies peer validation and often heralds a significant advancement in the field. The broader medical community and patient advocacy groups are likely to view these findings with cautious optimism, eagerly anticipating the next steps in SPI-1005’s development.

The Road Ahead: Future Directions and Impact

The latest Phase 3 analysis undeniably adds significant weight to the growing body of evidence supporting further investigation of SPI-1005 for inner-ear disorders. If ultimately proven safe and effective and granted regulatory approval, SPI-1005 could represent a paradigm shift in the management of Ménière’s disease, offering the first oral, disease-modifying treatment capable of directly addressing the debilitating hearing loss component.

Beyond Ménière’s, the prospect of an oral therapeutic for sudden sensorineural hearing loss is particularly compelling. The challenges in treating SSNHL are substantial, often involving a narrow therapeutic window and the invasiveness of intratympanic injections for local corticosteroid delivery. An oral agent like SPI-1005, if proven effective, could offer a more convenient and potentially more accessible treatment option, significantly impacting patient outcomes and quality of life. The company is actively studying the treatment for several other inner-ear conditions, including noise-induced hearing loss, tinnitus, and hearing-related complications associated with certain antibiotics (ototoxicity) and chemotherapy drugs. This broad pipeline reflects a strategic vision to tackle a spectrum of often debilitating auditory and vestibular conditions.

The journey from promising clinical data to approved therapy is long and arduous, requiring successful completion of all regulatory hurdles, including potentially additional pivotal trials for new indications like SSNHL. However, the current findings provide a strong foundation for continued research and development, holding the promise of bringing much-needed relief to millions suffering from inner ear disorders. The global market for hearing loss treatments is substantial and growing, driven by an aging population and increasing awareness of auditory health. A novel, effective, and orally administered drug like SPI-1005 could capture a significant share of this market, transforming the therapeutic landscape for these challenging conditions.

About Sound Pharmaceuticals
Sound Pharmaceuticals is a privately held biotechnology company based in Seattle, Washington, dedicated to developing investigational treatments for a range of hearing and balance disorders. Its lead candidate, SPI-1005, is currently being evaluated across multiple neurotologic indications with the aim of addressing significant unmet medical needs. For more information, visit soundpharma.com.

Source: Sound Pharmaceuticals